Prevention of neuropathology in the mouse model of Hurler syndrome

Annals of Neurology

Volumn 56, Issue 1, 2004, Pages 68-76

  Desmaris, Nathalie ^a   Verot, Lucie ^b   Puech, Jean Philippe ^c   Caillaud, Catherine ^c   Vanier, Marie Thérèse ^b   Heard, Jean Michel ^a  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

^c INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATAN SULFATE; GANGLIOSIDE GM2; GANGLIOSIDE GM3; HEPARAN SULFATE; LEVO IDURONIDASE;

ADENO ASSOCIATED VIRUS; ADENOVIRUS 2; ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBELLUM; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME DEFECT; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC CODE; HEMISPHERE; HURLER SYNDROME; MOUSE; MUCOPOLYSACCHARIDOSIS; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REPRODUCIBILITY; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRUS STRAIN;

ANIMALS; BRAIN; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GANGLIOSIDES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IDURONIDASE; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; MUCOPOLYSACCHARIDOSIS I;

EID: 3042836949     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20150     Document Type: Article

References (54)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill, 2001:3421-3452.
2. Russel RC, Hendson G, Jevon G, et al. Murine MPS I: insights into the pathogenesis of Hurler syndrome. Clin Genet 1998;53:349-361.
3. Constantopoulos G, Iqbal K, Dekaban AS. Mucopolysaccharidosis IH, IS, II and IIIA: glycosaminoglycans and lipids of isolated brain cells and other fractions from autopsied tissues. J Neurochem 1980;34:1399-1411.
4. Constantopoulos G, Shull RM, Hastings N, Neufeld EF. Neurochemical characterization of canine alpha-L-iduronidase deficiency disease. J Neurochem 1985;45:1213-1217.
5. Fratantoni J, Hall C, Neufeld E. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 1968;162:570-572.
6. Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344:182-188.
7. Birkenmeier EH, Davisson MT, Beamer WG, et al. Murine mucopolysaccharidosis type VII. Characterization of a mouse with β-glucuronidase deficiency. J Clin Invest 1989;83:1258-1266.
8. Bosch A, Heard JM. Gene therapy for mucopolysaccharidosis. Int Rev Neurobiol 2003;55:271-296.
9. Kornfeld S. Structure and function of the mannose-6-phosphate receptor/insuline growth factor II receptor. Annu Rev Biochem 1992;61:307-330.
10. Dittmer F, Ulbrich EJ, Hafner A, et al. Alternative mechanism for trafficking of lysosomal enzymes in mannose 6-phosphate receptor-deficient mice are cell type-specific. J Cell Sci 1999;112:1591-1597.
11. Shull RM, Kakkis ED, McEntee MF, et al. Enzyme replacement in a canine model of Hurler syndrome. Proc Natl Acad Sci USA 1994;91:12937-12941.
12. Kakkis ED, MaEntee MF, Schmidtchen A, et al. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med 1996;58:156-167.
13. Xiao X, McCown TJ, Li J, et al. Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) alpha1 containing receptors and increases inferior collicular seizure sensitivity. Brain Res 1997;756:76-83.
14. Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994;8:148-154.
15. Bankiewicz KS, Eberling JL, Kohutnicka M, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000;164:2-14.
16. McCown TJ, Xiao X, Li J, et al. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res 1996;713:99-107.
17. Nakai H, Yant SR, Strom TA, et al. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 2001;75:6969-6976.
18. Wu P, Phillips MI, Bui J, Terwilliger EF. Adeno-associated virus vector-mediated transgene integration into neurons and other nondividing cell targets. J Virol 1998;72:5919-5926.
19. Passini MA, Watson DJ, Vite CH, et al. Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice. J Virol 2003;77:7034-7040.
20. Davidson BL, Stein CS, Heth JA, et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA 2000;97:3428-3432.
21. Clarke LA, Russel CS, Pownall S, et al. Murine mucopolysaccaridosis type I: targeted disruption of the murine alpha-L-iduronidase gene. Hum Mol Genet 1997;6:503-511.
22. Zheng Y, Zhou J, Rozengurt N, et al. Treatment of the mouse model of MPSI by transplantation of bone marrow and of genetically modified bone marrow. Am J Hum Genet 2001;69(suppl):679.
23. Samulski RJ, Chang LS, Shenk T. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol 1987;61:3096-3101.
24. Chiorini JA, Kim F, Yang L, Kotin RM. Cloning and characterization of adeno-associated virus type 5. J Virol 1999;73:1309-1319.
25. Adra CN, Boer PH, McBurney M. Cloning and expression of the mouse pgk-1 gene and the nucleotide sequence of its promoter. Gene 1987;60:65-74.
26. Salvetti A, Moullier P, Cornet V, et al. In vivo delivery of human α-L-iduronidase in mice implanted with neo-organs. Hum Gene Ther 1995;6:1153-1159.
27. Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999;73:2886-2892.
28. Goodwin E, Rottman F. The 3' flanking sequence of the bovine growth hormone gene contains novel elements required for efficient and accurate polyadenylation. J Biol Chem 1992;267:16330-16334.
29. Grimm D, Kern A, Rittner K, Kleinschmidt J. Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther 1998;9:2745-2760.
30. Brument N, Morenweiser R, Blouin V, et al. A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes -2 and -5. Mol Ther 2002;6:678-686.
31. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998;72:2224-2232.
32. Zolotukhin S, Byrne BJ, Mason E, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999;6:973-985.
33. Salvetti A, Orève S, Chadeuf G, et al. Factors influencing recombinant adeno-associated virus production. Hum Gene Ther 1998;9:695-706.
34. Ohmi K, Greenberg DS, Rajavel K, et al. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA 2003;100:1902-1907.
35. Kakkis ED, Matynia A, Jonas AJ, Neufeld EF. Overexpression of the human lysosomal enzyme alpha-L-iduronidase in Chinese hamster ovary cells. Protein Expt Putif 1994;5:225-232.
36. Fujita N, Suzuki K, Vanier MT, et al. Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum Mol Genet 1996;5:711-725.
37. Kyrklund T. Two procedures to remove polar contaminants from a crude brain lipid extract by using prepacked reverse-phase columns. Lipids 1987;22:274-277.
38. Sferra TJ, Qu G, McNeely D, et al. Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse. Hum Gene Ther 2000;11:507-519.
39. Bosch A, Perret E, Desmaris N, Heard JM. Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol Ther 2000;1:63-70.
40. Skorupa AF, Fischer KJ, Wilson JM, et al. Sustained production of β-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in mucopolysaccharidosis VII mice. Exp Neurol 1999;160:17-27.
41. Brooks AI, Stein CS, Hughes SM, et al. Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc Natl Acad Sci USA 2002;99:6216-6221.
42. Bosch A, Perret E, Desmaris N, et al. Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum Gene Ther 2000;11:1139-1150.
43. Ghodsi A, Stein C, Derksen T, et al. Extensive B-glucuronidase activity in murine central nervous system after adenovirus-mediated gene transfer to brain. Hum Gene Ther 1998;9:2331-2340.
44. Xia H, Mao Q, Davidson BL. The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors. Nat Biotechnol 2001;19:640-644.
45. Ross CJ, Ralph M, Chang PL. Somatic gene therapy for a neurodegenerative disease using microencapsulated recombinant cells. Exp Neurol 2000;166:276-286.
46. Elliger SS, Elliger CA, Aguilar CP, et al. Elimination of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus vector. Gene Ther 1999;6:1175-1178.
47. Fu H, Samulski RJ, McCown TJ, et al. Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIb mouse model by adeno-associated virus-mediated gene delivery. Mol Ther 2002;5:42-49.
48. Consiglio A, Quattrini A, Martino S, et al. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat Med 2001;7:310-316.
49. Flotte JR, Afione SA, Slow R, et al. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem 1993;268:3781-3790.
50. Walkley SU, Baker HJ, Rattazzi MC, et al. Neuroaxonal dystrophy in neuronal storage disorders: evidence for major GABAergic neuron involvement. J Neurol Sci 1991;104:1-8.
51. Huang JQ, Trasler JM, Igdoura S, et al. Apoptotic cell death in mouse models of GM2 gangliosidosis and observation on human Tay-Sachs and Sandhoff diseases. Hum Mol Genet 1997;6:1879-1885.
52. Walkley SU, Haskins ME, Shull R. Alterations in neuron morphology in mucopolysaccharidosis type I. Acta Neuropathol 1988;75:611-620.
53. Ashton LJ, Brooks DA, McCourt PAG, et al. Immunoquatification and enzyme kinetics of alpha-L-iduronidase in cultured fibroblasts from normal and controls and mucopolysaccharidosis type I patients. Am J Hum Genet 1992;50:787-794.
54. Shull RM, Munger RJ, Spellacy E, et al. Canine α-L-iduronidase deficiency: a model of mucopolysaccharidosis I. Am J Pathol 1982;109:244-248.